CorMedix Targets REZZAYO Expansion Amid DefenCath Reimbursement Shift

What happened

CorMedix CEO outlined plans to potentially expand REZZAYO into fungal infection prophylaxis while working to sustain DefenCath utilization through the upcoming federal reimbursement change. The DeepValue report underscores that the stock's valuation at $7.03 already prices in a significant hit from the July 1, 2026 TDAPA step-down, leaving little room for error. Management's commentary suggests they are actively pursuing pipeline catalysts and commercial execution to offset the looming pricing reset. However, the fundamental risk remains that dialysis providers may force earlier price concessions, compressing the 1H26 revenue bridge. The company's guidance implies a low-single-digit EV/EBITDA multiple if Melinta synergies hold, but the thesis relies on verifying unit adoption through near-term KPI disclosures.

Implication

With the company emphasizing REZZAYO expansion and DefenCath volume maintenance, investors should focus on Q2 2026 Phase 3 ReSPECT data and any disclosed adoption metrics from the Analyst Day. The stock's low valuation (EV/EBITDA ~4-5x) reflects skepticism about post-TDAPA economics, but positive data could drive a re-rating. However, without improved visibility on 2H26 DefenCath net pricing, the thesis remains a policy timing bet. The CEO's proactive messaging is encouraging but not proof of execution; position sizing must account for binary catalyst risk and the July 2026 cliff.

Thesis delta

The May 2026 article reinforces management's multi-pronged strategy to counterbalance DefenCath's reimbursement step-down with REZZAYO pipeline expansion and commercial focus. This does not alter the base-case scenario but slightly increases the probability of a positive catalyst outcome. The core thesis remains unchanged: buy only if near-term unit adoption KPIs and REZZAYO data validate the utilization offset; otherwise, the stock remains a high-risk timing play.